Novo Nordisk has unveiled plans to invest $80 million in expanding facilities at its production site in Måløv, Denmark.   The facility currently manufactures products for oral diabetes treatments and will be expanded to ensure capacity for future production of these products. The project is expected to be completed in 2022.   “This investment in our production facilities in Måløv is an important step in building and ensuring future capacity for production of Rybelsus (oral semaglutide). Målø...